8-K - Greenland Mines Ltd (0001907223) (Filer)

8-K - Greenland Mines Ltd (0001907223) (Filer)

8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)

8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)

8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)

424B3 - Klotho Neurosciences, Inc. (0001907223) (Filer)

8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)

DEFR14A - Klotho Neurosciences, Inc. (0001907223) (Filer)

DEF 14A - Klotho Neurosciences, Inc. (0001907223) (Filer)

PRE 14A - Klotho Neurosciences, Inc. (0001907223) (Filer)

Company to hold investor webcast on March 12, 2026 at 4:15PM ET to discuss its expanded focus on critical minerals development in Greenland CHARLOTTE, N.C., March 12, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces that it changed its corporate name to Greenland Mines Ltd and its stock ticker to "GRML" effective at market open today, Thursday, March 12, 2026. No action will be required by existing shareholders — shares held in brokerage accounts will be automatically updated to reflect the new symbol. The Company will hol

Company to hold investor webcast on March 12, 2026 at 4:15PM ET to discuss its expanded focus on critical minerals development in Greenland CHARLOTTE, N.C., March 9, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces that it is changing its corporate name to Greenland Mines Ltd and its stock ticker to "GRML" effective at market open on Thursday, March 12, 2026. No action will be required by existing shareholders — shares held in brokerage accounts will be automatically updated to reflect the new symbol. The rebranding and ti

Transaction delivers shareholders direct ownership in one of the largest undeveloped palladium-gold deposits on Earth, establishing a new western champion in critical mineral supply security; Company to rebrand as Greenland MinesCHARLOTTE, N.C. and NUUK, Greenland, March 4, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces the acquisition of Greenland Mines Corp. ("Greenland Mines" or "GMC"), a privately held Delaware corporation that controls an 80% interest in, and an option to acquire the remaining 20% of, the Skaergaard Project in Southeast Greenland — one of the largest and most significant undeveloped palladium, gold, and platinum

The Company enlists industry veteran Dr. Bret Barnes to oversee the development of new diagnostic offeringsNEW YORK, Feb. 24, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. ("Klotho" or the Company) announces the development of two genomics-based diagnostic tests that will be utilized in Klotho's clinical trials and to be provided as a service in the field of longevity and the understanding of the relationships between biological age and chronologic age.   One genomics test being developed is a quantitative DNA methylation assay that determines the extent of DNA methylation of

NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the Company) announces the acceptance of 18 claims within a patent application filed in Australia for composition and use of human secreted Klotho protein ("s-KL") isoform of the human gene sequence. The Australian government entity IP Australia has notified the Company and the licensor of the technology, Universitat Autonoma de Barcelona, that these claims are to be granted. The 18 claims cover the use of a human muscle-cell specific promoter operatively linked to a nucleic acid gene sequence encoding human the human s-KL protein for treating motor impairment. The claims also cover the use of neuro

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO, ", Klotho", , or ", the Company", )), a U.S.-based biogenetics company, announces that CEO Dr. Joseph Sinkule will be presenting at the 2026 Biotech Showcase in San Francisco on January 13, 2026 at 11:30AM PT.  The Biotech Showcase is to be held January 12-14, 2026 at the Hilton San Francisco Union Square. At the event, the Company will be available for one-on-one meetings with investors and potential partners. To request a meeting, please contact [email protected]. About Klotho Neuroscien

NEW YORK, Nov. 7, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) (the "Company" or "Klotho"), a U.S.-based biogenetics company, announces it has been selected as winner of the Fifth Annual BioTech Breakthrough Award in the "Cell Therapy Innovation of the Year" category. Klotho Neurosciences earned this recognition for its pioneering work developing transformative gene and cell therapies using a patented, secreted form of the human Klotho gene (s-KL) to address devastating neurodegenerative and age-related diseases, including ALS, Alzheimer's disease, and Parkins

NEW YORK, Oct. 16, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO, ", Klotho", , or ", the Company", )) a U.S.-based biogenetics company, announces that members of its leadership team will attend Longevity Biotech 2025 in Boston, Massachusetts, on October 22–23, 2025. The conference convenes leaders across biotech, pharma, academia, and venture to advance the development of longevity therapeutics and will be hosted at Wightman Mansion (43 Hawes Street, Brookline/Fenway campus). At the event, the Company will be available for one-on-one meetings with investors and

NEW YORK, Oct. 7, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO, ", Klotho", , or ", the Company", )) today announced that its Letter of Intent with Turn Biotechnologies was allowed to expire by the parties. Following careful evaluation, Klotho's Board of Directors determined that the proposed transaction did not fit its long-term strategic plan. Instead, the Company will focus its resources on advancing its Klotho anti-aging protein research pipeline and development of treatments, where it sees the greatest opportunity to deliver value for patients and sharehol

NEW YORK and PALO ALTO, Calif., Sept. 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO, ", Klotho", or ", the Company", )) today announced it has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies, Inc. ("Turn"), a leader in induced pluripotent stem cells (iPSC) and cellular reprogramming. The proposed cash and stock transaction is subject to completion of due diligence, execution of a definitive agreement, and customary closing conditions. If completed, the transaction would position Klotho as a leader in the development of longevity therapeutics.

4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

Transaction delivers shareholders direct ownership in one of the largest undeveloped palladium-gold deposits on Earth, establishing a new western champion in critical mineral supply security; Company to rebrand as Greenland MinesCHARLOTTE, N.C. and NUUK, Greenland, March 4, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces the acquisition of Greenland Mines Corp. ("Greenland Mines" or "GMC"), a privately held Delaware corporation that controls an 80% interest in, and an option to acquire the remaining 20% of, the Skaergaard Project in Southeast Greenland — one of the largest and most significant undeveloped palladium, gold, and platinum

Company to hold investor webcast on March 12, 2026 at 4:15PM ET to discuss its expanded focus on critical minerals development in Greenland CHARLOTTE, N.C., March 12, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces that it changed its corporate name to Greenland Mines Ltd and its stock ticker to "GRML" effective at market open today, Thursday, March 12, 2026. No action will be required by existing shareholders — shares held in brokerage accounts will be automatically updated to reflect the new symbol. The Company will hol

Company to hold investor webcast on March 12, 2026 at 4:15PM ET to discuss its expanded focus on critical minerals development in Greenland CHARLOTTE, N.C., March 9, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces that it is changing its corporate name to Greenland Mines Ltd and its stock ticker to "GRML" effective at market open on Thursday, March 12, 2026. No action will be required by existing shareholders — shares held in brokerage accounts will be automatically updated to reflect the new symbol. The rebranding and ti

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer's and Parkinson's disease is proud to announce the appointment of Dr. Merit Cudkowicz, MD, MSc, to its Scientific Advisory Board (SAB). Dr. Cudkowicz is the Chair of Neurology at MGH, Director of the Sean M. Healey & AMG Center for ALS, and is the Julieanne Dorn Professor of Neurology at Harvard Medical School. A member of the National Academy of Medicine, Dr. Cudkowicz has been a leading clinician in promoting and devising more efficient methods for the development of thera

NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related disorders, including ALS, Alzheimer's, and Parkinson's, today announced the appointment of Riad El-Dada, former US President of Merck, to its Board of Directors. With decades of leadership in the pharmaceutical industry, Mr. El-Dada brings extensive experience in product development, commercialization, and strategic partnerships. During his tenure as US President of Merck, he oversaw commercial teams across a dozen therapeutic areas, managing over $12 billion in revenue. Prior to that role, he ser

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ:KLTO), a leading biotechnology company focused on developing cell and gene therapies for aging and age-related diseases, is proud to announce the appointment of Dr. Makoto Kuro-o to its Scientific Advisory Board. Dr. Kuro-o, a distinguished Japanese physician-scientist, is widely recognized as the pioneer behind the discovery of the Klotho gene, often referred to as the "anti-aging gene." While conducting groundbreaking research at the National Institute of Neuroscience in Tokyo, Dr. Kuro-o and his team identified the Klotho gene while studying mice engineered to overexpress a gene linked to premature aging. Th

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ:KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for aging and age-related diseases, today announced the appointment of Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its Chief Operating Officer (COO). Dr. Joseph Sinkule, Chairman, CEO, and Founder of Klotho Neurosciences, welcomed Moriarty to the leadership team: "We are thrilled to have Peter join Klotho Neurosciences as COO. His extensive experience across the pharmaceutical industry, both in the U.S. and globally, will be instrumental as we move forward. Peter has a remarkable track record, including leadership roles at